Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for HE in HBV-ACLF
NCT05786859Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rifaximin in hepatic encephalopathy (HE) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Reversal rate of hepatic encephalopathy at 4 weeks. Status: unknown.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05786859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786859.